Analyst Price Targets — TENX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 22, 2026 10:43 am | — | Guggenheim | $40.00 | $12.00 | TheFly | Tenax Therapeutics price target raised to $40 from $34 at Guggenheim |
| June 22, 2026 10:09 am | — | Chardan Capital | $27.00 | $12.00 | TheFly | Tenax Therapeutics initiated with a Buy at Chardan |
| December 17, 2025 11:50 am | — | Guggenheim | $25.00 | $11.16 | TheFly | Tenax Therapeutics price target raised to $25 from $14 at Guggenheim |
| September 8, 2025 8:53 am | Yasmeen Rahimi | Piper Sandler | $20.00 | $6.04 | TheFly | Tenax Therapeutics initiated with an Overweight at Piper Sandler |
| May 15, 2025 1:20 pm | Seamus Fernandez | Guggenheim | $15.00 | $5.70 | TheFly | Tenax Therapeutics price target lowered to $15 from $16 at Guggenheim |
| March 10, 2025 10:22 am | — | Leerink Partners | $20.00 | $6.19 | StreetInsider | Tenax Therapeutics (TENX) PT Raised to $20 at Leerink PartnersMember Login |
Latest News for TENX
Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data readout for TNX-103 in PH-HFpEF. TNX-103 targets a large, unmet market with no approved therapies, but phase 3 success is uncertain despite promising phase 2 secondary endpoint results relating to 6MWD. The phase 3 LEVEL study is powered >90% to detect a 25-meter 6MWD change, but failure could cut TENX shares by 50% or…
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly…
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the…
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq:…
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TENX.
U.S. House Trading
No House trades found for TENX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.